RPA inhibitors designed to interfere with RPA binding to ssDNA or RPA phosphorylation are being investigated as cancer chemotherapeutics, including mitigation of tumor resistance to genotoxic chemotherapy [61,62]. The gene discussed is RPA1; the disease is cancer.